NCT06038630View on ClinicalTrials.gov

129Xe MRI Cardiopulmonary

PHASE2RecruitingINTERVENTIONAL
Enrollment

125

Participants

Timeline

Start Date

January 12, 2024

Primary Completion Date

June 30, 2028

Study Completion Date

June 30, 2028

Conditions
Interstitial Lung DiseaseChronic Thromboembolic Pulmonary HypertensionAcute Pulmonary EmbolismAnemiaPolycythemiaDyspnea
Interventions
DRUG

Hyperpolarized Xe129

Hyperpolarized xenon will be administered in multiple doses in volumes up to 25% of subject TLC followed by a breath hold of up to 15 seconds.

OTHER

Oxygen Administration

Oxygen administration

Trial Locations (1)

27710

RECRUITING

Duke University Medical Center, Durham

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

lead

Bastiaan Driehuys

OTHER